By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BIND Therapeutics 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-3400 Fax: 617-491-0351


SEARCH JOBS








Company News
BIND Therapeutics (BIND) Announces FDA Authorization Of First-in-Human Clinical Trial With AstraZeneca PLC (AZN)’s Aurora B Kinase Inhibitor Accurin AZD2811 6/23/2015 11:36:58 AM
BIND Therapeutics (BIND) Appoints Andrew Hirsch as President and Chief Executive Officer 6/22/2015 8:43:30 AM
BIND Therapeutics (BIND) To Present At JMP Securities Life Sciences Conference 2015 6/16/2015 11:32:01 AM
BIND Therapeutics (BIND) And Macrophage Therapeutics Announce Collaboration To Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform 6/11/2015 10:00:30 AM
BIND Therapeutics (BIND) And Macrophage Therapeutics Announce Collaboration To Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform 6/11/2015 8:48:06 AM
BIND Therapeutics (BIND) Reports First Quarter 2015 Financial Results And Provides Corporate Update 5/7/2015 12:50:54 PM
BIND Therapeutics (BIND) To Report First Quarter 2015 Financial Results On May 7, 2015 4/28/2015 12:05:16 PM
BIND Therapeutics (BIND) Presents Data Highlighting Ability Of Accurins To Control Biodistribution And Accumulate In Target Tissue At AACR Annual Meeting 2015 4/22/2015 9:01:15 AM
BIND Therapeutics (BIND) Announces Extension Of Global Collaboration With Pfizer (PFE) To Develop And Commercialize Multiple Accurins 4/3/2015 8:33:47 AM
Data From Three Abstracts Validating Potential Of BIND Therapeutics (BIND)’ Accurins To Be Presented At American Association for Cancer Research Annual Meeting 3/19/2015 12:48:18 PM
12345678910
//-->